S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:ATNX

Athenex - ATNX Competitors

$0.54
+0.02 (+3.87%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.52
$0.55
50-Day Range
$0.41
$1.11
52-Week Range
$0.41
$3.91
Volume
2.91 million shs
Average Volume
1.31 million shs
Market Capitalization
$65.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

ATNX vs. ATNM, ATOS, EPIX, CRMD, HOWL, NBTX, VIRX, IFRX, NXTC, and FBIO

Should you be buying Athenex stock or one of its competitors? The main competitors of Athenex include Actinium Pharmaceuticals (ATNM), Atossa Therapeutics (ATOS), ESSA Pharma (EPIX), CorMedix (CRMD), Werewolf Therapeutics (HOWL), Nanobiotix (NBTX), Viracta Therapeutics (VIRX), InflaRx (IFRX), NextCure (NXTC), and Fortress Biotech (FBIO). These companies are all part of the "pharmaceutical preparations" industry.

Athenex vs.

Athenex (NASDAQ:ATNX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.

40.9% of Athenex shares are held by institutional investors. Comparatively, 8.9% of Actinium Pharmaceuticals shares are held by institutional investors. 12.0% of Athenex shares are held by insiders. Comparatively, 1.3% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has lower revenue, but higher earnings than Athenex.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athenex$120.18 million0.54-$199.77 million-$1.72-0.31
Actinium Pharmaceuticals$1.14 million125.60-$24.77 millionN/AN/A

Athenex has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Athenex received 293 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 65.84% of users gave Athenex an outperform vote while only 0.00% of users gave Actinium Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
AthenexOutperform Votes
293
65.84%
Underperform Votes
152
34.16%
Actinium PharmaceuticalsOutperform Votes
No Votes
Underperform Votes
2
100.00%

Athenex currently has a consensus price target of $4.00, indicating a potential upside of 645.99%. Given Athenex's higher probable upside, analysts plainly believe Athenex is more favorable than Actinium Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athenex
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Athenex has a net margin of -160.39% compared to Actinium Pharmaceuticals' net margin of -1,681.46%. Actinium Pharmaceuticals' return on equity of -32.44% beat Athenex's return on equity.

Company Net Margins Return on Equity Return on Assets
Athenex -160.39% -258.81% -43.21%
Actinium Pharmaceuticals -1,681.46% -32.44% -30.36%

In the previous week, Athenex had 14 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 15 mentions for Athenex and 1 mentions for Actinium Pharmaceuticals. Athenex's average media sentiment score of 0.67 beat Actinium Pharmaceuticals' score of 0.00 indicating that Athenex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Athenex
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Actinium Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Athenex beats Actinium Pharmaceuticals on 11 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATNX vs. The Competition

MetricAthenexPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$65.21M$5.63B$4.41B$6.38B
Dividend YieldN/A2.41%7.26%3.17%
P/E Ratio-0.3110.66123.5518.51
Price / Sales0.54468.132,950.75128.88
Price / CashN/A21.8222.8929.84
Price / Book1.688.656.466.21
Net Income-$199.77M$187.51M$166.90M$239.70M
7 Day Performance-51.25%5.67%4.70%4.54%
1 Month Performance-9.73%11.47%10.80%12.20%
1 Year Performance-83.55%-31.64%-27.19%-20.33%

Athenex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATNM
Actinium Pharmaceuticals
0 of 5 stars
$5.65
+4.4%
N/AN/A$134.39M$1.14M0.0032
ATOS
Atossa Therapeutics
0 of 5 stars
$1.05
+7.1%
N/A-64.6%$132.96MN/A-5.836Positive News
Gap Up
EPIX
ESSA Pharma
2.3978 of 5 stars
$3.01
+1.3%
$21.00
+597.7%
-74.8%$132.49MN/A-3.5025Analyst Revision
News Coverage
Positive News
CRMD
CorMedix
0 of 5 stars
$3.38
+5.6%
N/AN/A$132.24M$190,000.00-4.6929Earnings Report
High Trading Volume
HOWL
Werewolf Therapeutics
2.441 of 5 stars
$4.78
+4.1%
$24.25
+407.3%
-60.2%$132.19MN/A-0.8639Short Interest ↓
Gap Up
NBTX
Nanobiotix
1.4695 of 5 stars
$3.96
+2.1%
N/A-64.7%$137.91M$3.13M0.0098Positive News
VIRX
Viracta Therapeutics
2.5865 of 5 stars
$3.69
+6.3%
$21.00
+469.1%
-56.9%$138.33M$2.07M-2.9824Positive News
IFRX
InflaRx
1.979 of 5 stars
$3.14
+3.3%
$7.00
+122.9%
+12.4%$138.80MN/A-3.1455Short Interest ↑
NXTC
NextCure
2.3684 of 5 stars
$5.04
+3.1%
$15.00
+197.6%
-28.0%$139.85M$22.38M-1.9087
FBIO
Fortress Biotech
2.4884 of 5 stars
$1.21
+9.0%
$9.60
+693.4%
-58.8%$129.97M$68.79M-1.41173Analyst Downgrade
Short Interest ↓
This page (NASDAQ:ATNX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.